Compare AGM & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | IVA |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | France |
| Employees | N/A | 84 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | AGM | IVA |
|---|---|---|
| Price | $158.14 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $215.00 | $16.20 |
| AVG Volume (30 Days) | 104.3K | ★ 390.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.27 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $146.69 | $2.70 |
| 52 Week High | $210.64 | $7.98 |
| Indicator | AGM | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 47.76 |
| Support Level | $156.98 | $5.71 |
| Resistance Level | $168.85 | $6.48 |
| Average True Range (ATR) | 6.07 | 0.30 |
| MACD | -1.09 | -0.06 |
| Stochastic Oscillator | 35.13 | 25.32 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.